CONTENTS

Contributors xiii
Foreword xv
Preface xvii
Preface to the First Edition xix
Acknowledgments xxi
Organization of the Book xxiii
User Agreement xxv

PART I
TRANSFORMING PROTEINS AND GENES INTO DRUGS—THE SCIENCE AND THE ART 1

1 Introduction to Biopharmaceuticals 3
   Abstract 3
   1.1 Background and Significance 4
   1.2 Translation of Biotechnology for Developing Biopharmaceuticals 7
   1.3 Historical Perspective of Pharmaceutical Biotechnology 8
   1.4 Distinctions between Chemical Drugs Versus Biopharmaceuticals 8
   1.5 Summary 10

2 Distinctions of Biologic Versus Small Molecule Platforms in Drug Development 13
   Abstract 13
   2.1 Introduction 14
   2.2 Transforming New Molecules into Drugs: The Drug Development Process 14
   2.3 Key Differences between Biotechnology and Chemical Products 16
   2.4 Current Trends in Drug Development 18
   2.5 Summary 22

3 Financing Biologic Drug Development 23
   Abstract 23
   3.1 Introduction 24
   3.2 The Role of the Orphan Drug Act 27
   3.3 Clinical Leverage Strategy in Accelerating Drug Development 30
   3.4 Therapeutic Target Considerations 32
   3.5 Evolving Trends 34
   3.6 Summary 36
4 Application of Biotechnology in Drug Discovery and Early Development

4.1 Introduction

4.2 Data Mining, Molecular Cloning, and Characterization

4.3 Optimization of Cell Expression Systems and Product Yield

4.4 Molecular Optimization

4.5 Proteins and Genes as Targets for Drug Discovery and Development

4.6 Summary

5 Large-Scale Production of Recombinant Proteins

5.1 Introduction

5.2 Yield Optimization in Genetic Constructs and Host Cells

5.3 Large-Scale Cultivation of Host Cells

5.4 Downstream Processing and Purification

5.5 Quality Assurance and Quality Control

5.6 Summary

6 Clinical Pharmacology, Toxicology, and Therapeutic Dosage and Response

6.1 Introduction

6.2 Clinical Pharmacology and Toxicology

6.3 Dose and Therapeutic Response

6.4 Dosage Form and Route of Administration

6.5 Summary

7 Clinical Evaluation and Regulatory Approval and Enforcement of Biopharmaceuticals

7.1 Introduction: Biologic Drug Development and Approval

7.2 Licensing of Biological Products

7.3 Preclinical and Clinical Testing

7.4 FDA Review and Approval Process

7.5 Regulatory Enforcement

7.6 Globalization of Drug Approval (Chien*)

7.7 Summary

8 Pharmacoeconomics and Drug Pricing (Garrison*)

8.1 Introduction: Pharmacoeconomics

8.2 Cost-Effectiveness: Assessing the Value of Biopharmaceuticals

8.3 The Cost of Developing Biopharmaceuticals

8.4 Pricing Biopharmaceuticals

8.5 Drug Development Incentives

8.6 Economics of Biosimilars

8.7 Economic Impact of Personalized Medicine

8.8 Summary and Future Challenges

*Contributing author
PART II
THERAPEUTIC AND CLINICAL APPLICATIONS OF BIOPHARMACEUTICALS—PROTEINS AND NUCLEIC ACIDS

9  Antibodies and Derivatives
   Abstract
   Section One
   9.1 Molecular Characteristics and Therapeutic Applications
      9.1.1 Introduction
      9.1.2 Historical Perspective—Discovery, Classification, Biodistribution, and Physiological Characteristics of Antibody Molecules
      9.1.3 Gamma Globulin and Hyperimmune Globulin
      9.1.4 Monoclonal Antibodies—From Mouse, Mouse-Human Chimeric, Humanized, to Human Monoclonal Antibodies
      9.1.5 Antibody Derivatives
      9.1.6 Disposition of Antibodies
      9.1.7 Extravascular Tissue Penetration
      9.1.8 Mechanisms of Antibody Bioactivities
      9.1.9 Antibody Conjugates
      9.1.10 Antibodies and Derivatives in Development
      9.1.11 Summary
   Section Two
   9.2 Antibodies and Derivatives Monographs List
   9.3 Antibodies and Derivatives Monographs

10  Hematopoietic Growth and Coagulation Factors
   Abstract
   Section One
   10.1 Molecular Characteristics and Therapeutic Applications
      10.1.1 Introduction
      10.1.2 Hematopoietic Growth and Coagulation Factors
      10.1.3 Therapeutic Use of Hematopoietic Growth Factors (Molineux, Elliott*)
      10.1.4 Therapeutic Use of Coagulation and Anticoagulation Factors
      10.1.5 Summary
   Section Two
   10.2 Hematopoietic Growth and Coagulation Factors List
   10.3 Hematopoietic Growth and Coagulation Factors Monographs

11  Cytokines and Interferons
   Abstract
   Section One
   11.1 Molecular Characteristics and Therapeutic Applications
      11.1.1 Introduction
      11.1.2 Interleukins as Immunotherapeutics
      11.1.3 Interferon Biology and Cancer Therapy (Tiu, Koon, Borden*)
      11.1.4 Interferons as Antiviral Therapy
      11.1.5 Interferons in Multiple Sclerosis
      11.1.6 Summary

* Contributing author
Section Two
11.2 Cytokines and Interferons Monographs List
11.3 Cytokines and Interferons Monographs

12 Hormones
Abstract
Section One
12.1 Molecular Characteristics and Therapeutic Applications
  12.1.1 Introduction
  12.1.2 Peptide Hormones and Clinical Significance
  12.1.3 Therapeutic Application of Recombinant and Synthetic Hormones
  12.1.4 Summary
Section Two
12.2 Hormones Monographs List
12.3 Hormones Monographs

13 Enzymes
Abstract
Section One
13.1 Molecular Characteristics and Therapeutic Applications
  13.1.1 Introduction
  13.1.2 Enzyme Replacement Therapy
  13.1.3 Enzymes as Therapeutic Agents
  13.1.4 Summary and Future Prospects
Section Two
13.2 Enzymes Monographs List
13.3 Enzymes Monographs

14 Vaccines (Hu, Ho*)
Abstract
Section One
14.1 Molecular Characteristics and Therapeutic Applications
  14.1.1 Vaccines and Their Impact on Human Health
  14.1.2 How Vaccines Work: Interplay Among Immune System, Diseases, and Vaccines
  14.1.3 Traditional Vaccine Approaches
  14.1.4 Subcellular and Recombinant Subunit Vaccines
  14.1.5 Vaccine Adjuvants
  14.1.6 Mode and Route of Vaccine Delivery
  14.1.7 Future Directions
  14.1.8 Summary
Section Two
14.2 Vaccines Monographs List
14.3 Vaccines Monographs

15 Other Biopharmaceutical Products
Abstract
15.1 Other Biopharmaceutical Products Monographs List
15.2 Other Biopharmaceutical Products Monographs

* Contributing author
PART III
FUTURE DIRECTIONS

16 Advanced Drug Delivery

Abstract
16.1 Introduction
16.2 Drug Therapeutic Index and Clinical Impact
16.3 Routes of Therapeutic Protein Administration
16.4 Physiological and Mechanistic Approaches
16.5 Approaches Using Devices
16.6 Molecular Approaches
16.7 Summary

17 Advances in Personalized Medicine: Pharmacogenetics in Drug Therapy

Abstract
17.1 Introduction to Interindividual Variation
17.2 Historical Perspective on Pharmacogenetics in Drug Safety and Efficacy
17.3 Pharmacogenetics in Drug Disposition and Pharmacokinetics
17.4 Pharmacogenetics in Drug Effects and Pharmacodynamics
17.5 Individualized Gene-Based Medicine: A Mixed Blessing
17.6 Current and Future Prospects of Pharmacogenetics
17.7 Summary

18 Gene and Cell Therapy

Abstract
18.1 Overview
18.2 General Strategies in Gene and Cell Therapy
18.3 Gene and Cell Therapy for Select Medical Conditions
18.4 Gene Therapy Research, Development, and Clinical Use (*Sullivan*)
18.5 Stem Cells in Regenerative Medicine and Diagnostics (*Kelly*)
18.6 Summary

19 Integration of Discovery and Development: The Role of Genomics, Proteomics, and Metabolomics

Abstract
19.1 Overview
19.2 Integration of Discovery and Development of Therapeutic Candidates
19.3 Genomics: The First Link between Sequences and Drug Targets
19.4 Proteomics: From Sequences to Functions
19.5 Metabolomics: Metabolic Profile Elucidation
19.6 Integrating Genomic, Proteomic, and Metabolomic Tools to Accelerate Drug Development
19.7 Summary

20 Pharmacoeconomics, Outcome, and Health Technology Assessment Research in Drug Development

Abstract
20.1 Introduction: Health-Care Decisions and Health Outcomes
20.2 Integration of Pharmacoeconomic Outcome Research in Clinical Drug Development

* Contributing author
20.3 Regional Differences in the Type of Evidence and Value Data Essential for Health-Care and Reimbursement Decisions 541
20.4 Biopharmaceutical Company Strategies 542
20.5 Summary 545
20.6 Acknowledgments 546

21 Future Prospects 547

Abstract 547
21.1 Progress and Benefits in Transforming Proteins and Genes into Biopharmaceuticals 548
21.2 Genomic Information Improves Safety and Production Cost of Biopharmaceuticals 548
21.3 The Business of Biopharmaceuticals and Economic Impacts 549
21.5 Public–Private Partnership in Financial and Regulatory Support to Improve Translational Success 550
21.6 Biopharmaceuticals and Public Health Benefits 551
21.7 Public Participation and Influence on Biopharmaceutical Development 551
21.8 Outlook 552

Appendix I. Dosage Form, Pharmacokinetics, and Disposition Data 555
Appendix II. Molecular Characteristics and Therapeutic Use 581
Appendix III. Nomenclature of Biotechnology Products 617
Appendix IV. Other Information 621
Index 633

Color plate section is located between pages 210 and 211.